CDK13 and prostate carcinoma: Our prior work in numerous prostate cancer models revealed the two kinases to have a synthetic lethal relationship—such that genetic ablation or pharmacologic inhibition of CDK13 preferentially impairs tumor cell survival in the setting of CDK12 inactivation (5).